During the past decade, Manhattan Medical Research conducted 54 clinical trials. In the 10-year time frame, 54 clinical trials started and 33 clinical trials were completed, i.e. on average, 61.1% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 22 clinical trials were completed. i.e. 157.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Manhattan Medical Research" #1 sponsor was "Eli Lilly and Company" with 7 trials, followed by "Allergan" with 5 trials sponsored, "Pfizer" with 4 trials sponsored, "UroGen Pharma Ltd." with 4 trials sponsored and "GTx" with 4 trials sponsored. Other sponsors include 35 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Manhattan Medical Research" #1 collaborator was "Syneos Health" with 2 trials as a collaborator, "American College of Radiology" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "ClinLogix. LLC" with 1 trials as a collaborator and "Crohn's and Colitis Foundation" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Manhattan Medical Research" are "Bladder Cancer" (5 trials), "Diabetes Mellitus, Type 2" (4 trials), "Overactive Bladder" (4 trials), "Premature Ejaculation" (4 trials) and "Urothelial Carcinoma Bladder" (4 trials). Many other conditions were trialed in "Manhattan Medical Research" in a lesser frequency.

Most popular intervention types in "Manhattan Medical Research" are "Drug" (49 trials), "Biological" (8 trials), "Device" (8 trials), "Other" (7 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Metformin" (3 trials), "UGN-102" (3 trials), "Dulaglutide" (2 trials) and "GTx-024" (2 trials). Other intervention names were less common.

The vast majority of trials in "Manhattan Medical Research" are 36 trials for "All" genders, 22 trials for "Male" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Manhattan Medical Research". undefined are not yet recruiting, 7 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 38 completed trials in Manhattan Medical Research, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Manhattan Medical Research, 2 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 6 trials that are defined as “Not Applicable".